⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IBRX News
ImmunityBio, Inc. Common Stock
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
globenewswire.com
IBRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
accessnewswire.com
IBRX
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA ® Plus CAR-NK, Chemo-Free Therapy
businesswire.com
IBRX
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA ® in BCG-Unresponsive Papillary Bladder Cancer
businesswire.com
IBRX
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
prnewswire.com
GTBP
IBRX
ERAS
CHRS
NBP
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
businesswire.com
IBRX
ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG
businesswire.com
IBRX
ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
businesswire.com
IBRX
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
globenewswire.com
ONCY
IBRX
BNTX
CMPX
Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA ® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
businesswire.com
IBRX